IVVD Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Invivyd Inc (IVVD) is not a good buy right now for a Beginner long-term investor with $50,000-$100,000 to deploy. The stock has some speculative upside from the VYD2311 program, but the current trend is still bearish, hedge funds are selling, and there is no strong proprietary buy signal. For an impatient investor, this is not an attractive entry today; the better call is to hold off.
IVVD is technically weak despite being oversold. RSI_6 at 11.858 shows extreme oversold conditions, but the MACD histogram is negative and still expanding, which confirms downside momentum. The moving averages are bearish with SMA_200 > SMA_20 > SMA_5, showing a persistent downtrend. Price at 0.8234 pre-market is sitting near support at 0.832 and above the lower support at 0.716, while resistance is first at 1.019 and then 1.206. The near-term pattern data also points to weakness, with an expected -1.72% over the next week and -3.86% over the next month.
["First participants have been dosed in the Phase 3 LIBERTY trial for VYD2311.", "The trial milestone supports progress toward a potentially important biologics license application for VYD2311.", "H.C. Wainwright reiterated a Buy rating and kept a $10 price target, calling the post-earnings selloff overdone."]
["Hedge funds are selling, with selling up 433.14% over the last quarter.", "The stock had a post-earnings selloff tied to a Q1 revenue miss and higher-than-expected R&D expense of $30.7M.", "Technical trend remains bearish with negative MACD and weak moving averages.", "No recent congress trading data is available.", "No signal on given stock today from AI Stock Picker or SwingMax.", "Short-term trend expectations are negative based on similar candlestick pattern analysis."]
No usable financial snapshot was provided because of an error, so the latest quarter cannot be fully assessed. The only clear financial takeaway is that Q1 revenue missed expectations and R&D expense was higher at $30.7M, which pressured the stock. The analyst comment suggests this expense increase was driven by pivotal spend ahead of the VYD2311 readout in Q3, but there is no complete quarter-over-quarter or year-over-year growth data available.
Recent analyst sentiment is still constructive. H.C. Wainwright reiterated Buy on 2026-05-14 and maintained a $10 price target, arguing the selloff was overdone and that the key value driver is the potential BLA for VYD2311. Wall Street pros appear bullish on the long-term pipeline thesis, but the broader market behavior, hedge fund selling, and weak price action show that the bearish case is currently dominating trading sentiment.
